AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31642245
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose bortezomib (1.0-1.3 mg/m2) on day 1, day 4, day 8, and day 11, with 21 days as a chemotherapy cycle.
Trial: 31642245
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose bortezomib (1.6 mg/m2) on day 1, day 8, day 15, and day 22, with 35 days as a chemotherapy cycle.
Trial: 15119752
Drug: Epinastine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinastine 10 mg plus pseudoephedrine 120 mg
Trial: 11694895
Drug: 60 degrees
RxNorm normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 degrees tilt drug-free
Trial: 11694895
Drug: 80 degrees
RxNorm normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 degrees tilt drug-free
Trial: 11694895
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion at 60 degrees
Trial: 11694895
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion at 80 degrees
Trial: 9126518
Drug: Injury prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injury prevention campaign on Naxos involving trained local collaborators providing weekly visits and advice.
Trial: 3122880
Drug: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (up to 100 mg/kg/day)
Trial: 3122880
Drug: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one with ascorbic acid
Trial: 3122880
Drug: Subcutaneous desferrioxamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous desferrioxamine (at comparable dose)
Trial: 23939511
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day baclofen
Trial: 23939511
Drug: 75 mg/day
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/day baclofen
Trial: 23939511
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day baclofen (in pharmacokinetic and cue-reactivity component)
Trial: 23939511
Drug: 75 mg/day
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/day baclofen (in pharmacokinetic and cue-reactivity component)
Trial: 21560488
Drug: Siriraj Mite
RxNorm normalized name: mite extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siriraj Mite Allergen Vaccine (SMAV) Dp at 2,500 AU/ml
Trial: 21560488
Drug: Siriraj Mite
RxNorm normalized name: mite extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siriraj Mite Allergen Vaccine (SMAV) Dp at 10,000 AU/ml
Trial: 21560488
Drug: Siriraj Mite
RxNorm normalized name: mite extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siriraj Mite Allergen Vaccine (SMAV) Df at 10,000 AU/ml
Trial: 21560488
Drug: Commercial standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial standardized mite allergen vaccine Dp at 2,500 AU/ml
Trial: 21560488
Drug: Commercial standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial standardized mite allergen vaccine Df at all concentrations
Trial: 15466644
Drug: Candesartan, titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan, titrated to 32 mg QD
Trial: 9584032
Drug: Safe Dates
RxNorm normalized name: Date
DrugBank: Date (DB10632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safe Dates program (treatment)
Trial: 23593643
Drug: G1: no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G1: no treatment
Trial: 19393405
Drug: Liquid alginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid alginate suspension
Trial: 1446992
Drug: Flunarizine (Fz)
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (Fz) 10 mg/d
Trial: 31524938
Drug: Adding diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding diabetes medications; 410 participants rated importance of 7 factors.
Trial: 31524938
Drug: Stopping diabetes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping diabetes medications; 408 participants rated importance of 7 factors.
Trial: 21558567
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training (TG; twice per week for 12 weeks)
Trial: 20137540
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg/d) and probucol (500 mg/d) for 4 weeks (combination group)
Trial: 20137540
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg/d) for 4 weeks (atorvastatin group)
Trial: 20137540
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Atorvastatin and combination)
Trial: 16316886
Drug: Tailored hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored hypnotic induction
Trial: 16316886
Drug: Manualized hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manualized hypnotic induction (Palsson's protocol)
Trial: 11575866
Drug: Rasagiline (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (0.5, 1, and 2 mg/d)
Trial: 9059469
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy (for patients with best CPAP use)
Trial: 9059469
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy (compliance comparison)
Trial: 7903218
Drug: Propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160 mg (SR)
Trial: 29860473
Drug: Macimorelin (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macimorelin (single-dose oral)
Trial: 28270180
Drug: Active acupressure
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active acupressure therapy (PC6, LI4, HT7 acupressure performed three times a day for 2 days)
Trial: 26009822
Drug: Subjective evaluation
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective evaluation of sublingual microcirculation images by physicians and nurses
Trial: 23534046
Drug: Fluorinex treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorinex treatment
Trial: 21636013
Drug: Vitamin B₆
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B₆ intake (median daily intake of 0.9 mg/day, range 0.6-1.5 mg/day)
Trial: 10891912
Drug: Naratriptan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naratriptan 1.5 mg
Trial: 8838506
Drug: Rheumatoid arthritis
RxNorm normalized name: Rheumatoid arthritis nuclear antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheumatoid arthritis (RA) patients receiving low dose methotrexate (MTX)
Trial: 8838506
Drug: Rheumatoid arthritis
RxNorm normalized name: Rheumatoid arthritis nuclear antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheumatoid arthritis (RA) patients not receiving low dose methotrexate (MTX)
Trial: 1486071
Drug: 0.3% gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% gentamicin ophthalmic solution
Trial: 30191262
Drug: Laquinimod (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laquinimod (0.6 mg/day)
Trial: 25515217
Drug: Multifaceted quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted quality improvement intervention for CVD risk management including electronic decision support, patient risk communication tools, computerized audit and feedback tools, and monthly peer-ranked performance feedback via a web portal.
Trial: 7985829
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g fish oil (group A)
Trial: 7985829
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g placebo Italian olive oil (group B)
Trial: 26093363
Drug: Intensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive periodontal disease treatment during mid-pregnancy (20-28 weeks' gestation)
Trial: 26093363
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same treatment postnatally)
Trial: 26093363
Drug: Intensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive periodontal disease treatment
Trial: 24434527
Drug: Bupropion 150
RxNorm normalized name: BUPROPION 150MG (SMK-C) 12HR SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 150 mg/d as an open-label add-on therapy (n = 5)
Trial: 24434527
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment (valproate and aripiprazole) without bupropion (n = 7)
Trial: 23031335
Drug: Beta-blocker treatment
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker treatment for 3 months
Trial: 23031335
Drug: Combined alpha/beta-blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined alpha/beta-blocker treatment for 3 months
Trial: 11529364
Drug: Kenacort‐A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kenacort‐A injection into the right tonsillar fossa
Trial: 19752608
Drug: Intrarectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine gel and 5 ml bupivacaine (0.25%) injected into periprostatic area
Trial: 19752608
Drug: Intrarectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine gel and 5 ml ropivacaine (0.25%) injected into periprostatic area
Trial: 17697548
Drug: TACE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE plus thalidomide (200 mg/d for 1-6 months)
Trial: 14973801
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron supplementation with iron III‐hydroxide sucrose complex (IHSC)
Trial: 14973801
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron and a single dose of r‐HuEPO (300 U/kg)
Trial: 11214126
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg sulphate oral glucosamine once daily for 3 years
Trial: 11214126
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 3 years
Trial: 6937788
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml cows' milk (double-blind challenge)
Trial: 28502735
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium dialysate (LCD; 1.25mmol/L)
Trial: 28502735
Drug: Standard calcium
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard calcium dialysate (SCD; 1.5mmol/L)
Trial: 22483238
Drug: Taeumjowi-tang (TJ001)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taeumjowi-tang (TJ001) 7 g three times daily for 12 weeks
Trial: 20400000
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen administration
Trial: 18074413
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg once a day
Trial: 18074413
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg two times a day
Trial: 18074413
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hypoglycemic treatment)
Trial: 10408729
Drug: MN rgp120
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN rgp120 HIV-1 vaccine (booster)
Trial: 10408729
Drug: MN and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN and IIIB rgp120 HIV-1 vaccines (coadministered)
Trial: 8900242
Drug: Met-985 insulin-receptor
RxNorm normalized name: Met
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Met-985 insulin-receptor variant
Trial: 8900242
Drug: Normal oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal oral glucose tolerance test
Trial: 6143187
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml intradermally at 8 sites
Trial: 6143187
Drug: 8-site intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-site intradermal vaccination with large dose of HRIG
Trial: 30365961
Drug: CPB flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPB flow rate of 2.4 L · min‐1 · m‐2
Trial: 30365961
Drug: CPB flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPB flow rate of 2.7 L · min‐1 · m‐2
Trial: 30365961
Drug: CPB flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPB flow rate of 3.0 L · min‐1 · m‐2
Trial: 30365961
Drug: CPB flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPB flow rates of 2.4, 2.7, and 3.0 L · min‐1 · m‐2
Trial: 30285672
Drug: Transdiagnostic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic group cognitive-behaviour therapy (tCBT) - 12 weekly 2-hour group sessions following a manualized treatment protocol
Trial: 21055582
Drug: Fixed orthodontic
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed orthodontic treatment with chemically cured resin
Trial: 21055582
Drug: Fixed orthodontic
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed orthodontic treatment with light-cured resin
Trial: 17986056
Drug: Low-dose UVA1
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose UVA1 phototherapy (40 J/cm²), 3 times weekly for 14 weeks
Trial: 16179665
Drug: Modafinil split
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil split doses
Trial: 16179665
Drug: Modafinil once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil once-daily (200 mg)
Trial: 12487756
Drug: Medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication plus 1 g/day Spirulina (group II)
Trial: 12487756
Drug: Medication (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (group I)
Trial: 7621847
Drug: Diltiazem formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem formulation 1
Trial: 7621847
Drug: Diltiazem formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem formulation 2
Trial: 2196108
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum (CP) plus chemotherapy (l-phenylalanine mustard (L-PAM) and 5-fluorouracil (PF))
Trial: 2196108
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (l-phenylalanine mustard (L-PAM) and 5-fluorouracil (PF))
Trial: 100818
Drug: Oral methylphenidate
RxNorm normalized name: methylphenidate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylphenidate (1.0 mg/kg)
Trial: 30799062
Drug: Directly observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly observed treatment (DOT)
Trial: 28962734
Drug: Combined orthodontic-periodontic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined orthodontic-periodontic treatment
Trial: 28962734
Drug: Basic periodontic
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic periodontic treatment
Trial: 23430315
Drug: Cholecalciferol (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (2000 IU daily for 6 weeks)
Trial: 19801932
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of L-alanine-L-glutamine dipeptide (0.40 g/kg/d; equal to 0.25 g of free glutamine) in Ala-Glu group (n = 212)
Trial: 29976501
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy (2 cycles of capecitabine and oxaliplatin: capecitabine 1700 mg/m2 per day from day 1 to 14, oxaliplatin 100 mg/m2 on day 1, every 3 weeks) after CRT.
Trial: 29976501
Drug: Preoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiation therapy (CRT) with capecitabine (50.4 Gy in 28 fractions) followed by TME.
Trial: 27871086
Drug: Foam cream
RxNorm normalized name: Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foam cream (active agent)
Trial: 27871086
Drug: Placebo foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo foam cream
Trial: 24762588
Drug: Omeprazole, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, amoxicillin, and clarithromycin for 1 week (T group)
Trial: 20485956
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of hyperbaric bupivacaine (10 mg) and sufentanil (5 microg)
Trial: 20485956
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of hyperbaric bupivacaine (10 mg) and sufentanil (5 microg)
Trial: 11952807
Drug: BQ‐123 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ‐123 (60 microg min(‐1)), a specific ETA‐receptor antagonist
Trial: 11952807
Drug: Ang II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ang II (0.65, 1.25, 2.5, 5 ng kg(‐1) min(‐1) for 15 min per dose level)
Trial: 10732594
Drug: Kogan's (1961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kogan's (1961) Attitude Toward Old People's Scale administered before clinical experiences
Trial: 10732594
Drug: Kogan's (1961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kogan's (1961) Attitude Toward Old People's Scale administered after clinical experiences
Trial: 7677537
Drug: Steroid regimen:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid regimen: 1 g of methylprednisolone sodium succinate intravenously before bypass and 4 mg of dexamethasone every 6 hours for four doses during the first 24 hours of recovery.
Trial: 2209305
Drug: Clonidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1 and 0.2 mg/day)
Trial: 2209305
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg 3 times/day)
Trial: 775954
Drug: Intravenous digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous digoxin (0.01 mg/kg over 10 minutes)
Trial: 28662677
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) with pembrolizumab (200 mg intravenously, every 3 weeks)
Trial: 23808756
Drug: Prescription headache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription headache medication
Trial: 21854276
Drug: Exercise as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise as an augmentation treatment
Trial: 8183752
Drug: Subcutaneous fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous fluid therapy (2 litres of dextrose-saline/24 hours)
Trial: 8183752
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid therapy (2 litres of dextrose-saline/24 hours)
Trial: 8183752
Drug: Subcutaneous fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous fluid therapy
Trial: 3070826
Drug: Ethamsylate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethamsylate (2 g/day in four equal doses)
Trial: 31865579
Drug: Plant-derived compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant-derived compounds with larvicidal activity; specific compounds not detailed
Trial: 29257140
Drug: Amitriptyline (AMI;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (AMI; 50 mg)
Trial: 29257140
Drug: Escitalopram (ESC;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (ESC; 10 mg)
Trial: 28160761
Drug: Nartana herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nartana herbal formulation (450 mg, 2 ×/d for first 15 d, then 1 ×/d)
Trial: 28160761
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg, 2 ×/d for first 15 d, then 100 mg, 1 ×/d)
Trial: 16918762
Drug: Dronabinol (DRO)
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol (DRO) 5 mg b.i.d.